Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Sees Significant Decrease in Short Interest

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the recipient of a significant decrease in short interest in December. As of December 31st, there was short interest totalling 108,500 shares, a decrease of 18.5% from the December 15th total of 133,100 shares. Approximately 7.9% of the company’s stock are sold short. Based on an average daily volume of 24,000 shares, the short-interest ratio is currently 4.5 days.

Alaunos Therapeutics Stock Down 4.8 %

Alaunos Therapeutics stock traded down $0.09 during trading hours on Thursday, reaching $1.70. 13,555 shares of the company were exchanged, compared to its average volume of 11,993. Alaunos Therapeutics has a 12 month low of $1.63 and a 12 month high of $32.85. The stock has a 50-day moving average of $2.11 and a 200 day moving average of $2.85.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.